摘要
目前国内医学界对非小细胞肺癌的治疗有几点共识:早期非小细胞肺癌(IA、IB、IIA、IIB)的治疗首选外科手术完全切除;可以完全切除的早期非小细胞肺癌术后不必做辅助性放疗;IIIA期(N2)非小细胞肺癌的术前诱导化疗(新辅助化疗)对提高手术切除率及改善生存期有一定得好处;可以完全切除的IA、IIB、IIA、IIB或IIIA期非小细胞肺癌的术后辅助化疗[1]。从患者可能存在微小病灶转移的角度上看是合理的;局部晚期非小细胞肺癌应用化疗与放疗结合疗法;转移性晚期非小细胞肺癌应用化疗优于最佳支持疗法,主张用以铂为基础的良药联合,化疗期限以四个周期为宜;晚期衰弱病人合理的支持疗法是需要的,伴有贫血的患者可以应用促红细胞生成素(EPO),可减少输血和改善生活质量[2]。在非小细胞肺癌的治疗方面存在共识的基础上也产生了治疗的亮点,在此基础上研究中医药治疗非小细胞肺癌的特色。
The medical profession has several consensus in the treatment of non-small cell lung cancer at present: The first treatment of early-stage non-small cell lung cancer (IA, IB, ⅡA, ⅡB) was complete resection surgical; Can be completely resected early stage non-small cell lung cancer needn't adjuvant radiotherapy; Phase IliA (N2) non-small ceU lung cancer induction chemotherapy before surgery (neoadjuvant chemotherapy) can improve the resection rate and has certain advantages to improve survival; Can be completely exci -sed IA, ⅡB, ⅡA, ⅡB, or ⅢA non-small cell lung cancer need adjuvant chemotherapy; It is reasonable in the view of the patient's may exist small lesions the transfer; Locally advanced non-small cell lung cancer apply chemotherapy plus radiation therapy; Metastatic advanced non-small cell lung cancer with chemotherapy is superior to best supportive care, advocating for the combined platinum-based medicine, the term of four cycles of chemotherapy is appropriate; Reasonable support frail patients with advanced treatment is needed, can be applied to patients with anemia associated with erythropoietin (EPO), can reduce blood transfusions and improve quality of life; In non-small cell lung cancer treatment based on the existence of a consensus treatment also produced a bright spot, and on base to study the chara -cteristics on treating non-small cell lung cance of in TCM.
出处
《中医临床研究》
2011年第8期17-18,共2页
Clinical Journal Of Chinese Medicine
关键词
中西医结合
非小细胞肺癌
临床研究
Integrative medicine
Non-small cell lung cancer
Clinical study